mitumomab

mAbexperimental

Mitumomab (BEC-2) is a mouse anti-BEC-2 monoclonal antibody investigated for the treatment of small cell lung carcinoma in combination with BCG vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the immune system. It was developed by ImClone and Merck. — Wikipedia

Clinical trial activity

3 trials · 9 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
3
Phase 3
3
Phase 4
0

Earliest trial started Mar 1, 1998 (NCT00003279)

Timeline

1990s

  1. Jan 1, 1998

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • Ganglioside GD3 other

    Mitumomab is an anti-idiotypic antibody that mimics GD3, a ganglioside that is expressed on the surface of tumor cells and is of neuroectodermal origin. Induce antibodies against GD3 ganglioside.

  • Ganglioside GD3Immunity, passive

    Ganglioside GD3 immunity, passive

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • bec2
  • bec2
  • mitumomab

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00006352Phase 3Sep 1, 1999European Organisation for Research and Treatment of Cancer, Leiden University
NCT00037713Phase 3Sep 1, 1998Cornell University, EORTC Lung Cancer Cooperative Group, Groupe Francais De Pneumo-Cancerologie, Imclone, Merck KGaA, Schweizerische Arbeitsgruppe fuer angewandte Krebsforschung, Spanish Lung Cancer Group
NCT00003279Phase 3Mar 1, 1998European Organisation for Research and Treatment of Cancer, Leiden University
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
European Organisation for Research and Treatment of CancerAcademic/Hospital2211998
Leiden UniversityAcademic/Hospital2011998
Cornell UniversityAcademic/Hospital1011998
EORTC Lung Cancer Cooperative GroupAcademic/Hospital1011998
Groupe Francais De Pneumo-CancerologieAcademic/Hospital1011998
ImcloneFor profit1111998
Merck KGaAFor profit1011998
Schweizerische Arbeitsgruppe fuer angewandte KrebsforschungAcademic/Hospital1011998
Spanish Lung Cancer GroupAcademic/Hospital1011998
9 organizations
Page 1 / 1